Arca
Skip to content
Tools
Tools

SSTR3: Somatostatin receptor type 3

Receptor for somatostatin-14 and -28.

  • Drugs that act on it: 2
  • Approved: 1
  • In phases 1 to 3: 1
  • Sponsors: 1

Who is on it, and how far along

Every drug ChEMBL records acting on SSTR3, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Protein or peptide 2

Approved1

  • Pasireotide

Phase 31

  • Vapreotide

Phase 20

    Phase 10

      The landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
      PasireotideApprovedNovartis PharmaceuticalsProtein or peptideAgonistSomatostatin receptor 3 agonist8
      VapreotidePhase 3—Protein or peptideAgonistSomatostatin receptor 3 agonist0

      Open trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 8 in all, from ClinicalTrials.gov.
      Managing Pasireotide-associated Hyperglycaemia in Acromegaly With Ketogenic DietPasireotideNot applicableRecruitingLeiden University Medical CenterOct 8, 2026
      Effects of Pasireotide Lar Therapy on Bone MetabolismPasireotide—RecruitingFondazione Policlinico Universitario Agostino Gemelli IRCCSSep 18, 2025
      Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NETPasireotidePhase 3RecruitingNovartis PharmaceuticalsJan 20, 2025
      Pasireotide as Maintenance Treatment in Synovial Sarcoma and Desmoplastic Small Round Cell TumorPasireotidePhase 2RecruitingUniversity Hospital HeidelbergJun 13, 2024
      A Study of Pasireotide in People With ProlactinomaPasireotidePhase 2RecruitingMemorial Sloan Kettering Cancer CenterMar 6, 2024
      Pasireotide s.c. in Patients With Post-Bariatric HypoglycaemiaPasireotidePhase 2Active, not recruitingRECORDATI GROUPJul 3, 2023
      Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NETPasireotidePhase 3Active, not recruitingAdvanced Accelerator ApplicationsJun 3, 2019
      HYPAR Trial - Hydrocortisone vs. Pasireotide in Reducing Pancreatic Surgery ComplicationsPasireotidePhase 4Active, not recruitingHelsinki University Central HospitalMay 17, 2016

      Diseases most associated with it

      Open Targets association score, 0 to 1; all associations
      • Neuroendocrine neoplasm0.57
      • Neoplasm0.56
      • ACTH-dependent Cushing syndrome0.48
      • Neuroendocrine carcinoma0.46
      • Digestive system neuroendocrine tumor, grade 1/20.40
      • Cancer0.40
      • Metastasis0.37
      • Hypothyroidism0.37

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2028, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P32745, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

      Esc

      Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

      Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.